• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Immunogen Inc (NQ: IMGN )

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EST, Feb 9, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Immunogen Inc

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    12 13 Next >
    3 Unstoppable Mega-Cap Stocks That Every Investor Should Own in 2024
    Dive into the world of three unstoppable mega-cap stocks leading the charge amidst the bullishness in the market. 
    Via InvestorPlace
    Amicus Therapeutics Stock Sees Improved Relative Strength Rating
    In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday. 
    Via Investor's Business Daily
    ImmunoGen Inc. (NASDAQ: IMGN) Near Top of Volume Charts in Thursday Trading
    Via Investor Brand Network
    3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List
    These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry. 
    Via InvestorPlace
    7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024
    Unveil these standout Russell 2000 stocks, meticulously picked to harness the potential of the evolving market landscape in the 2024 surge. 
    Via InvestorPlace
    Madrigal Pharmaceuticals Stock Shows Rising Relative Strength
    A Relative Strength Rating upgrade for Madrigal Pharmaceuticals shows improving technical performance. 
    Via Investor's Business Daily
    AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue and Profit Fall
    AbbVie reports Q4 earnings with adjusted EPS at $2.79, beating consensus. Sees FY 2024 EPS of $11.05-$11.25. Raises 2027 outlook for key products. 
    Via Benzinga
    ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From ImmunoGen, Inc.
    Via Business Wire
    Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
    Via Get News
    Exposures Product Safety
    AbbVie's Transformational 2023, Analyst Anticipates Growth in 2024 Amid Competitive Pressures
    AbbVie's growth outlook in 2024 as William Blair upgrades, highlighting strong performance in Humira erosion management, strategic acquisitions, and a 3.8% dividend yield. 
    Via Benzinga
    Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
    --News Direct-- 
    Via News Direct
    Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
    New York, Jan. 29, 2024 - (Plato Data) -- Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug... 
    Via TheNewswire.com
    Exposures Product Safety
    ABBV: This Top Biotech Just Went On A Buying Spree
    AbbVie stock is a buy following its recent merger & acquisition activity (Immunogen and Cerevel). 
    Via Talk Markets
    Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating
    Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
    Via Investor's Business Daily
    7 Dividend Aristocrats That Will Pay You for Years to Come
    If you're looking for a consistent income, consider some of these top Dividend Aristocrats to buy and hold in 2024. 
    Via InvestorPlace
    Ultragenyx Pharm Stock Earns IBD Stock Upgrade With RS Rating Jump To 83
    On Thursday, Ultragenyx Pharm stock just cleared that 80 or higher RS Rating benchmark with an upgrade from 75 to 83. 
    Via Investor's Business Daily
    Cassava Sciences Stock Continues Showing Rising Relative Strength
    Cassava Sciences sees its Relative Strength Rating move into the elite 90-plus level. 
    Via Investor's Business Daily
    Cramer Says This Major Healthcare Stock Is 'Ridiculously Cheap And Doing So Many Great Things'
    On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Realty Income (NYSE: O) and recommends staying with it. "It’s a very steady story," he noted. 
    Via Benzinga
    Is AbbVie Stock a Buy Now?
    The company is grappling with losing Humira's patent protection in 2023. 
    Via The Motley Fool
    Topics Intellectual Property
    Exposures Intellectual Property
    Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
    Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
    Via Investor's Business Daily
    ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From ImmunoGen, Inc.
    Via Business Wire
    3 Biotech Stocks Set for Breakthroughs in 2024
    With groundbreaking advancements in new medicine and science, 2024 holds a promising future for these biotech stocks. 
    Via InvestorPlace
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
    Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio. 
    Via MarketBeat
    Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
    According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.  
    Via Benzinga
    AbbVie's Recent ImmunoGen Acquisition Looks Brilliant: Here's Why
    The acquisition fills an immediate need with some extras to boot. 
    Via The Motley Fool
    3 Stocks at the Forefront of Medical Innovation
    Boring businesses and industries typically show new faces when technology comes around; today, these biotech stocks are leading the way. 
    Via InvestorPlace
    Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade
    On Thursday, Tarsus Pharmaceuticals stock reached a key technical milestone, seeing its Relative Strength Rating jump to 91 from 84. 
    Via Investor's Business Daily
    The 7 Most Undervalued Growth Stocks to Buy in December
    Buy these distressed names now and ride their share prices higher over the coming year as they stage a comeback. 
    Via InvestorPlace
    Cassava Sciences Stock Shows Rising Relative Strength Following 3 Up Days
    Cassava Sciences sees its Relative Strength Rating reach the 80-plus level. 
    Via Investor's Business Daily
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    12 13 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.